| Literature DB >> 31085757 |
James L Mohler1, Emmanuel S Antonarakis2, Andrew J Armstrong3, Anthony V D'Amico4, Brian J Davis5, Tanya Dorff6, James A Eastham7, Charles A Enke8, Thomas A Farrington9, Celestia S Higano10, Eric Mark Horwitz11, Michael Hurwitz12, Joseph E Ippolito13, Christopher J Kane14, Michael R Kuettel1, Joshua M Lang15, Jesse McKenney16, George Netto17, David F Penson18, Elizabeth R Plimack11, Julio M Pow-Sang19, Thomas J Pugh20, Sylvia Richey21, Mack Roach22, Stan Rosenfeld22, Edward Schaeffer23, Ahmad Shabsigh24, Eric J Small22, Daniel E Spratt25, Sandy Srinivas26, Jonathan Tward27, Dorothy A Shead28, Deborah A Freedman-Cass28.
Abstract
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.Entities:
Year: 2019 PMID： 31085757 DOI： 10.6004/jnccn.2019.0023
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908